Addition of antifibrotic therapy to immunosuppression in hypersensitivity pneumonitis: A case series

Hypersensitivity pneumonitis has historically been treated with immunosuppression, but recently nintedanib was approved for the treatment of progressive fibrotic HP. One limitation of INBUILD is that the only immunosuppression (IS) permitted at the time of enrollment was glucocorticoids at a dose of...

Descripción completa

Detalles Bibliográficos
Autores principales: Kypreos, Margaret, Barbera, Tyonn, Newton, Chad A., Glazer, Craig S., Adams, Traci N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8649083/
https://www.ncbi.nlm.nih.gov/pubmed/34926143
http://dx.doi.org/10.1016/j.rmcr.2021.101562

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8649083/
https://www.ncbi.nlm.nih.gov/pubmed/34926143
http://dx.doi.org/10.1016/j.rmcr.2021.101562

Ejemplares similares